MarketPulse

Duchenne muscular dystrophy

5 articles
BenzingaBenzinga··Atossa Therapeutics Inc

Atossa Therapeutics Advances (Z)-Endoxifen Pipeline With FDA Orphan Designations

Atossa Therapeutics reported Q1 2026 expenses of $9.9M, secured FDA orphan drug designation for lead candidate (Z)-endoxifen in rare diseases.
ATOSclinical developmentbreast cancer
GlobeNewswire Inc.GlobeNewswire Inc.··Nxera Pharma

Nxera Pharma Posts Strong Q1 2026 as Spinoff Centessa Fetches $7.8B Lilly Deal

Nxera Pharma reported JPY 11.3B Q1 revenue driven by R&D milestones. Spinoff Centessa agreed to $7.8B acquisition by Eli Lilly.
ABBVLLYCNTANBIXrevenue growthdrug discovery
BenzingaBenzinga··Upsher-Smith Laboratories, Llc

Upsher-Smith Expands DMD Support Infrastructure with New Patient, Clinician Platforms

Upsher-Smith launches digital support platforms for DMD treatment KYMBEE, enhancing patient access and clinician resources through comprehensive support program.
BORAYrare diseasepharmaceutical
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Mesoblast Wins FDA Green Light for Direct Path to DMD Approval Trial

Mesoblast receives IND clearance to proceed directly to registrational trial for Ryoncil in Duchenne muscular dystrophy, potentially accelerating path to market approval.
MESORyoncil®cell therapy
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Keros Therapeutics' Rinvatercept Shows Promise in Neuromuscular Disease Trial

Keros Therapeutics presented Phase 1 data for rinvatercept showing good tolerability and increased muscle mass, planning Phase 2 trials in DMD and ALS.
KROSPhase 1 clinical trialPhase 2 trials